Steven Sherman, MD, FACE, provides insight on the treatment of radioactive iodine-refractory differentiated thyroid cancer and the management of adverse events.
EP. 1: Overview of RAI-Refractory DTC
Steven Sherman, MD, FACE, provides an overview of the history and evolution of treating patients with RAI [radioactive iodine]–refractory differentiated thyroid cancer [DTC].
EP. 2: Phase 3 SELECT Trial
A review of the phase 3 SELECT trial examining the use of lenvatinib for the treatment of RAI-refractory DTC and the management of adverse events.
EP. 3: Dosing of TKI Therapy for RAI-Refractory DTC
A review of a multicenter phase 2 study evaluating the safety and efficacy of lenvatinib starting doses in RAI-refractory DTC.
EP. 4: Managing Adverse Events in RAI-Refractory DTC Therapy
An expert endocrinologist perspective on managing the toxicities associated with lenvatinib when treating RAI-refractory DTC and the role of dose reduction and interruption.
EP. 5: RAI-Refractory DTC: Patient Education of Systemic Therapy
Approaching patient education of RAI-refractory DTC therapy with lenvatinib, fostering open communication between patients and providers, and monitoring medication adherence.
EP. 6: Future Treatment Landscape of RAI-Refractory DTC
Steven Sherman, MD, FACE, provides closing thoughts on unmet needs and future directions for the treatment of patients with RAI-refractory DTC.
2 Clarke Drive Cranbury, NJ 08512